NCT06417086 Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers
| NCT ID | NCT06417086 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ZhanYJ |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 176 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 176 participants in total. It began in 2024-06-01 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if acupuncture works to treat mild-to-moderate Alzheimer's disease, as well as the difference of its effect in APOE e4 carriers and non-carriers. It will also learn about the safety of acupuncture. Researchers will compare acupuncture to a placebo (sham acupuncture) to see if acupuncture works to relieve the cognitive impairment and improve the ability of daily living and the quality of life. In addition, the plasma and neuroimaging biomarkers will be included as objective indexes. Participants will: Experience acupuncture or sham acupuncture 3 times per week for 12 weeks, and receive a 52-week follow-up. Visit the clinic at Week 12, Week 38 and Week 64 for checkups and tests.
Eligibility Criteria
Inclusion Criteria: * Aged between 50-85 years * Diagnosed by the criteria of Neurological Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) * Cognitive impairment based on the scores of the Chinese version of the Mini Mental State Examination (MMSE) (patients with mild to moderate Alzheimers disease, 11≤primary school degree≤22, 11≤junior high school degree or above≤26 * Magnetic resonance imaging (MRI) confirmation of atrophy of the hippocampus or the medial temporal lobe volume, MRI manifestation of high possibility of Alzheimer Disease * The Medial Temporal Lobe Atrophy Rating Scale (MTA-scale) score (≥2 for those under 75 years, and ≥3 for those over 75 years) * Voluntarily joining this study with informed consents Exclusion Criteria: * Cognitive impairment caused by other factors (e.g. vascular dementia, dementia with Lewy bodies, frontotemporal dementia, hormone or metabolic abnormalities, hypothyroidism, folic acid or vitamin B12 deficiency, delirium or other mental and emotional disorders (such as schizophrenia and depression)) * A serious heart condition, hepatic disease, renal system disease, hematopoietic system disease, or whole-body malnutrition * Aphasia, disturbance of consciousness, or failure to cooperate with the related examinations due to physical disability * Contraindications to undergoing an MRI scan such as claustrophobia or pacemaker implantation. * Anticoagulant treatments such as warfarin or heparin * Use of pacemakers or receiving acupuncture in the past 2 weeks
Contact & Investigator
Yijun Zhan
STUDY CHAIR
Shanghai University of Traditional Chinese Medicine
Frequently Asked Questions
Who can join the NCT06417086 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06417086 currently recruiting?
Yes, NCT06417086 is actively recruiting participants. Contact the research team at jenniferzhan_lhzj@163.com for enrollment information.
Where is the NCT06417086 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06417086 clinical trial?
NCT06417086 is sponsored by ZhanYJ. The principal investigator is Yijun Zhan at Shanghai University of Traditional Chinese Medicine. The trial plans to enroll 176 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.